Bentracimab

贝曲西单抗

Report date: 2022/11/05 14:35:14

Base Information

Drug NameBentracimab
Drug Alias NamePB-2452MEDI-2452
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Fab fragment
Mechanisms of ActionPlatelet aggregation modulators
TargetsNot applicable
Therapy Area/IndicationsBlood Loss, SurgicalHemorrhageThrombocytopenia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[13] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAstrazeneca PlcMedimmune
China Registration ClassN/A

Develop Information

Active CompaniesPhasebio Pharmaceuticals IncSfj Pharmaceuticals IncAlfasigma Spa +[5] 
Inactive CompaniesN/A
Active IndicationsBlood Loss, SurgicalHemorrhageThrombocytopenia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A